nichelle@dravetfoundation.org

Zhao grant

Establishing the role of the noradrenergic network during seizures in Dravet syndrome

Meiling Zhao, PhD – University of MichiganEstablishing the role of the noradrenergic network during seizures in Dravet syndromePostdoctoral Fellowship – $75,000, 1 year Grant Summary: Individuals with Dravet syndrome suffer from severe seizures that cannot be completely controlled by medications. While most epilepsy research has focused on the more superficial brain regions that we know […]

Establishing the role of the noradrenergic network during seizures in Dravet syndrome Read More »

Theyel grant

Abnormal ectopic action potentials in PV-INs: A novel pathophysiological mechanism in Dravet syndrome

Brian Theyel, MD, PhD – Brown UniversityAbnormal ectopic action potentials in PV-INs: A novel pathophysiological mechanism in Dravet syndromeResearch Grant – $250,000, 2 years Grant Summary: Dravet syndrome, which is caused by a mutation in the SCN1A gene, is a debilitating illness that emerges during the first year of life. It causes seizures, setbacks during development, speech and language

Abnormal ectopic action potentials in PV-INs: A novel pathophysiological mechanism in Dravet syndrome Read More »

Baraban Isom Parent grant

Therapeutic benefit of MGE progenitor cell transplantation in a rabbit model of Dravet syndrome

Lori L. Isom, PhD – University of MichiganScott Baraban, PhD – University of California San FranciscoJack M. Parent, MD – University of MichiganTherapeutic benefit of MGE progenitor cell transplantation in a rabbit model of Dravet syndromeTransformational Science Grant – $500,000, 3 years Grant Summary: Dravet syndrome (DS) is a devastating developmental and epileptic encephalopathy that

Therapeutic benefit of MGE progenitor cell transplantation in a rabbit model of Dravet syndrome Read More »

Abbott grant

Increasing clinical trial readiness in Dravet syndrome- Creation and pilot of Dravet-specific clinical outcome measures

Megan Abbott, MD – University of Colorado DenverIncreasing clinical trial readiness in Dravet syndrome- Creation and pilot of Dravet-specific clinical outcome measuresClinician-Researcher Award – $75,000, 1 year Grant Summary: Dravet syndrome (DS) is the most common genetic cause of Developmental and Epileptic Encephalopathy (DEE), yet there are no FDA approved disease modifying treatments. Current precision

Increasing clinical trial readiness in Dravet syndrome- Creation and pilot of Dravet-specific clinical outcome measures Read More »

Helbig Goldberg grant

Generating a shareable clinico-genomic data resource for Dravet syndrome 

Ingo Helbig, MD – The Children’s Hospital of PhiladelphiaEthan M. Goldberg, MD, PhD – The Children’s Hospital of PhiladelphiaGenerating a shareable clinico-genomic data resource for Dravet syndrome 2023 Genetic RFA – $1,000,000, 3 years Grant Summary: Individuals with Dravet syndrome can have different disease courses, and there are important differences in how seizure and development differences

Generating a shareable clinico-genomic data resource for Dravet syndrome  Read More »

Hill grant

Mechanistic investigation in a novel mouse model of early-onset SCN1A-related disorders

Sophie Hill, PhD – Children’s Hospital of PhiladelphiaMechanistic investigation in a novel mouse model of early-onset SCN1A-related disordersPostdoctoral Fellowship – $75,000, 1 year Grant Summary: Mutations in the SCN1A gene most commonly cause reduced functioning of the Nav1.1 protein and lead to Dravet syndrome, a debilitating epilepsy disorder. However, a new class of SCN1A mutations

Mechanistic investigation in a novel mouse model of early-onset SCN1A-related disorders Read More »

Brunklaus grant

SCN1A Horizons – A natural history study of SCN1A-related epilepsies in the United Kingdom

Andreas Brunklaus, MD – University of Glasgow, Royal Hospital for Children, Glasgow, UKSCN1A Horizons – A natural history study of SCN1A-related epilepsies in the United KingdomGrant Support £30,000 ($41,481 USD) Grant Summary: The SCN1A Horizons natural history study launched in November 2023 and will assess up to 400 pediatric and adult patients with SCN1A-related epilepsies, including Dravet

SCN1A Horizons – A natural history study of SCN1A-related epilepsies in the United Kingdom Read More »

social 5x7 3A3A6973 copy e1696507312578

Gail Farfel, PhD – Vice Chair

Gail brings more than 25 years of pharmaceutical development and regulatory rare disease experience with both large and small pharmaceutical companies. She was most recently the chief executive officer of ProMIS, a biotechnology company focused on the generation of antibody therapeutics for neurodegenerative diseases. Prior to ProMIS, Gail was the executive vice president and global

Gail Farfel, PhD – Vice Chair Read More »

Seizure Action Plan Coalition Logo

Seizure Action Plan Coalition

The Seizure Action Plan Coalition began in 2020 as a labor of love between the LGS Foundation, Dravet Syndrome Foundation, and TSC Alliance. The organizations knew there was an opportunity to bring the epilepsy community together to bring attention and awareness to Seizure Action Plans for people with epilepsy. The three organizations served as the Governing Organizations of the coalition

Seizure Action Plan Coalition Read More »

Neurology live logo

NeurologyLive Partner – Strategic Alliance Partnership

NeurologyLive®, is a multimedia platform dedicated to providing health care professionals with direct access to expert-driven, practice-changing news and insights in neurology. DSF is a member of their Strategic Alliance Partnership (SAP) program. The SAP program builds a community of advocacy groups, medical associations, and medical institutions to foster collaboration and an open exchange of

NeurologyLive Partner – Strategic Alliance Partnership Read More »

Scroll to Top

Join us at a Day of Dravet workshop